Artificial intelligence can potentially predict a patient's response to cancer treatment

The study was groundbreaking, not only for the deep-learning predictability, but also because it allowed researchers to see what the model learned about the immune system. "DeepTCR's predictive power is exciting," said Dr. John-William Sidhom, first author of the study, "but what I found more fascinating is that we were able to view what the model learned about the immune system's response to immunotherapy." He also mentioned the great potential for creating future medications with the information. "We can now exploit that information to develop more robust models, and possibly better treatment approaches, for many diseases, even those outside of oncology." DeepTCR was developed by Dr. Sidhom while he was an M.D./Ph.D student at the Johns Hopkins University School of Medicine.